# Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

> **NCT05068232** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 49 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Extensive-stage Small-cell Lung Cancer
- Lung Cancer

## Interventions

- **RADIATION:** Ablative Radiation
- **DRUG:** Durvalumab
- **DRUG:** Etoposide
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05068232
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-19
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05068232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05068232, "Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05068232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*